Semler Scientific, Inc. (NASDAQ:SMLR)

Semler Scientific  (OOTC:SMLR), a company that offers technology and software solutions to healthcare providers, announced Q2 2023 results:

• Sales of $18.6 million vs $14.8 million in the prior year, ahead of analyst estimates of $16.0 million

• EPS of $0.75 vs $0.51 in the prior year and beats analyst estimates of $0.56

"We are pleased to report once again record quarterly revenues and pre-tax net income predominately from sales of QuantaFlo® for peripheral arterial disease testing," said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. "We are encouraged by our results year to date and are highly focused on developing our business in heart dysfunction."

See our weekly wrap email from July 23, 2023 where we highlight SMLR as one of our most successful contributor picks.  The stock is well off highs due to the company announcing that Medicare and Medicaid reimbursement will be a lot less or a limited amount for one of its medical testing devices. We’re extremely interested in tracking SMLR. 

The conference call did not go into detail of the potential impact from the medicare/medicaid decision. The company stated it continues to focus on maintaining and enhancing revenue and profitability opportunities. 

“Our primary objective remains steadfast to maintain and enhance our current revenue opportunities and profitability. To achieve this, we are reinvesting in emerging growth opportunities, particularly focusing on new customers for QuantaFlo both for PAD and HD. This broadening of our customer base may prove to show the tremendous promise and the exciting potential that we believe is in our company's future.”

Semler Scientific, Inc. is a medical risk assessment company. The Company develops, manufactures and markets products that assist healthcare providers in monitoring patients and evaluating chronic diseases. The Company markets and licenses FloChec, which is a United States Food and Drug Administration (FDA) cleared product. FloChec is a four-minute in-office blood flow test. FloChec is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a tool for internists and primary care physicians to conduct blood flow measurements. It offers FloChec product to cardiologists, internists, nephrologists, endocrinologists, podiatrists and family practitioners. The Company's FloChec features a sensor clamp that is placed on the toe or finger much like pulse oximetry devices. The Company provides FloChec product and services through salespersons and through its distributor.

In April 2015, the company announced the launch of its multi-test service offering, WellChec™, to more comprehensively evaluate patients for chronic disease.